Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Gilead Sciences (GILD) and lowers the price target from $80 to $76.
April 29, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays maintains an Equal-Weight rating on Gilead Sciences and lowers the price target from $80 to $76.
The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in GILD's stock price. The maintenance of an Equal-Weight rating indicates that the analyst sees the stock as fairly valued at its current price, but the lowered price target suggests a reduced growth outlook or potential risks that could impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100